Skip to Main Content
CWRU Links
Case Comprehensive Cancer Center

Awards Requiring University Nomination

Awards Requiring University Nomination

Limited Submission: V Foundation for Cancer Research 2017 Translational Research Award

Internal Deadline: Friday, February 24, 2017 at 5p ET
Nomination Deadline: Tuesday, March 14, 2017 at 5p ET
Translational Application Deadline: Tuesday, May 2, 2017 at 5p ET

The Case Comprehensive Cancer Center is invited to submit TWO nominees for consideration for the Translational Award, if at least one of the two nominee applicants is submitting a research project that focuses on the biological basis of cancer disparities experienced by patients from minority ethnic or racial populations in cancer causes, aggressiveness, treatment or relapse. Minorities for the purposes of this application are defined as African Americans or people of African descent, Pacific Islanders, Hispanic Americans and Native Americans and Alaskan Natives. 

Special Focus area: As in previous years, any area of cancer research is permitted. However, research on cancers that are more prevalent or aggressive in specific ethnic populations is encouraged, but not required. Cancers in which ethnic and racial disparities have previously been shown include: lung and bronchus, colon and rectum, breast, prostate, uterine, cervix, stomach and liver. As in 2016, among our highly ranked finalists for the 2017 Translational Award program, we will designate at least one of the highest ranked applications as the recipient of a Stuart Scott Memorial Fund Translational Research Award. While not required, we have a special interest in supporting immune oncology and immunotherapy research, when applicable.

Definition of a translational research project: Translational projects should move a novel strategy from the laboratory into a human clinical trial or use specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than 3 years. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial.

Eligibility Criteria

Institution Eligibility:

  • Only research institutions who received this invitation may submit a nominee for consideration. Other affiliates of the institution who did not receive the email are not eligible to nominate an applicant.
  • Institutions must be non-profit research institutions in the US or Canada. 

Applicant Eligibility:

All nominated applicants must be leading a Translational Award research team. The applicant must meet all of the following criteria to be eligible to submit an application:

  • The nominee must be nominated by their Cancer Center Director if the research institution is a cancer center. If the research institution is not a cancer center, then the provost, dean or other senior research administrative official who is responsible for the internal nominee selection process may make the nomination. We do not review unsolicited applications.
  • Applicant must be employed at a non-profit research institution (e.g. 501c3, Section 170).
  • By the Due Date of the Application, applicants who will lead this research team must have all the following:
    • Be scientists who hold a tenure-track faculty position at their cancer research institution. Non-promotable, adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for Principal Investigator nomination to lead the Translational Research Team.
    • Applicants must be either US Citizens or have a legal permit to work in the USA (either temporary or permanent).

The Translational Research Award is a $600,000 grant awarded in three annual installments of $200,000. More information about this award is available on the V Foundation website:  

Nomination Process
To be considered for the nomination, submit a one-page LOI and biosketch to Kristin Waite ( by Friday, February 24, 2017. 

Kristin Waite, PhD
Case Comprehensive Cancer Center